MS Detection of Somatic Mutations in Hematological Malignancies

Evaluation of MassArray Platform Versus Illumina Miseq for the Detection of Driver Mutations in Hematological Malignancies

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03771079

Acronym

MAHM

Enrollment

200

Registered

2018-12-10

Start date

2018-12-01

Completion date

2019-12-31

Last updated

2018-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological Malignancy

Keywords

Hematological Malignancy, mutations, NGS sequencing, mass spectrometry

Brief summary

Detection of somatic mutations in hematological malignancies is now routinely assessed by NGS sequencing. This powerful approach is nevertheless time consuming and its costs represent limitation for its availability. An original approach is now available, using mass spectrometry (MS). In this study the analytical performance of both methods will be compared, using samples that were previously analyzed by NGS. The goal of the study is to assess whether MS can represent or not a faster and cheaper way to detect key point mutations in patients suffering from hematological malignancies

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adults \>18 years old * anonymized samples already studied with NGS in Strasbourg university hematology center for somatic mutations * non-opposition of the patient for testing the archive sample with the new method

Exclusion criteria

* opposition for testing the archive sample with the new method * insufficient archival material * patient under protection

Design outcomes

Primary

Measure	Time frame	Description
Detection of somatic mutations in hematological malignancies by using mass spectrometry (MS)	10 months	Detection of somatic mutations in hematological malignancies is now routinely assessed by NGS sequencing. This powerful approach is nevertheless time consuming and its costs represent limitation for its availability. An original approach is now available, using mass spectrometry (MS). In this study the analytical performance of both methods will be compared, using samples that were previously analyzed by NGS.

Countries

France

Contacts

Primary ContactLaurent MAUVIEUX, MD, PhD

laurent.mauvieux@chru-strasbourg.fr33 3 88 12 75 27

Outcome results